Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼ºÀåÈ£¸£¸ó ºÐºñ ³úÇϼöü¼±Á¾ÀÇ Ä¡·áÀü·« Treatment Strategy of Growth Hormone Secreting Pituitary Adenoma

´ëÇѽŰæ¿Ü°úÇÐȸÁö 1998³â 27±Ç 12È£ p.1682 ~ 1686
·ù±ÇÀÇ, ÇÏÀ±, ±è¿µ¾Æ,
¼Ò¼Ó »ó¼¼Á¤º¸
·ù±ÇÀÇ (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ¿Ü°úÇб³½Ç

ÇÏÀ± (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ¿Ü°úÇб³½Ç
±è¿µ¾Æ (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ¿Ü°úÇб³½Ç

Abstract

¼­·Ð
¼ºÀåÈ£¸£¸óºÐºñ ³úÇϼöü¼±Á¾ÀÇ Ä¡·á´Â ¼ö¼úÀû ¹æ¹ý°ú °í½ÄÀûÀÎ ¹æ»ç¼±Ä¡·á(conventional
radiation therapy)°¡ ÁÖ·Î »ç¿ëµÇ¾úÀ¸¸ç ÃÖ±Ù µé¾î octreotide¿Í bromocriptineµîÀ» ÀÌ¿ëÇÑ
¾à¹°Ä¡·á¿Í Gammma-knife surgeryµîÀÇ ¹æ»ç¼±Ä¡·á°¡ º¸Á¶¿ä¹ýÀ¸·Î ½ÃÇàµÇ°í ÀÖ´Ù. ¼ºÀåÈ£
¸£¸óºÐºñ ³úÇϼöü¼±Á¾ÀÇ Ä¡·áÀÇ ¸ñÇ¥´Â Á¤»ó ³úÇϼöü±â´ÉÀ» ȸº¹½ÃÅ°°í Á¾±«¿¡ ÀÇÇÑ ÁÖº¯
Á¶Á÷ÀÇ ¾Ð¹ÚÀ» ÇؼҽÃÅ°¸ç, ´ç´¢º´, °íÇ÷¾Ð µî°ú °°Àº ³»°úÀûÀ¸·Î ½±°Ô Ä¡·áµÇÁö ¾Ê´Â ÀÓ»ó
Áõ»óÀ» °³¼±½ÃÅ°´Â °ÍÀÌ´Ù. ¼ö¼úÀû Ä¡·á¹æ¹ýÀ¸·Î´Â °æÁ¢Çüµ¿¼ö¼ú¹ý (transsphenoidal
appro-ach, TSA)ÀÌ °¡Àå ¾ÈÀüÇÏ°í È¿°úÀûÀÎ ¹æ¹ýÀ¸·Î ÀÎÁ¤µÇ°í ÀÖÀ¸³ª. ¼ö¼ú·Î ¿ÏÀüÇÑ Á¾
¾çÀÇ Á¦°Å°¡ ÀÌ·ç¾îÁöÁö ¸øÇÏ¸é ¹æ»ç¼±Ä¡·á°¡ ÁÖµÈ º¸Á¶Àû Ä¡·á¹æ¹ýÀ¸·Î »ç¿ëµÇ¾î¿Ô´Ù. ±×
·¯³ª Áö±Ý±îÁö ÈçÈ÷ »ç¿ëµÇ¾î¿Â °í½ÄÀû ¹æ»ç¼±Ä¡·á´Â ³úÇϼöü ±â´É ÀúÇÏÁõ(6¡­67%)µî ¹æ
»ç¼±Ä¡·áÇÕº´ÁõÀÌ ¹ß»ýÇÒ °¡´É¼ºÀÌ ³ô´Ù. ¶ÇÇÑ ³úÇϼöü ¼±Á¾Àº º´¸®ÇÐÀûÀ¸·Î ´ëºÎºÐ ¾ç¼º
Á¾¾çÀ¸·Î Á¾¾çÀÇ Àç¹ßÀÌ ÁøÁ¤ÇÑ ÀǹÌÀÇ Àç¹ß(recurrent)À̶ó±â º¸´Ù´Â ¼ö¼ú½Ã ¿ÏÀüÈ÷ Á¦°ÅÇÏ
Áö ¸øÇÑ ÀÜ¿©Á¾¾çÀÌ ´Ù½Ã ¼ºÀåÇßÀ» °¡´É¼ºÀÌ ³ôÀ¸¹Ç·Î °¡´ÉÇÑÇÑ Á¾¾çÀ» ¿ÏÀüÈ÷ ÀûÃâÇÏ°ÔµÇ
¸é ¾à¹°Ä¡·á ¹× ¹æ»çÀüÄ¡·áµîÀÇ Ãß°¡Ä¡·áÀÇ Çʿ伺À» °¨¼Ò½ÃÄÑ ÀÌ·ÎÀÎÇÑ ÇÕº´ÁõÀ» ÇÇÇÒ ¼ö
ÀÖÀ» °ÍÀ¸·Î »ç·áµÈ´Ù. µû¶ó¼­ º» ±³½Ç¿¡¼­´Â Áö³­ 4³â°£ ÀüÇâÀû ¿¬±¸·Î ¼ºÀåÈ£¸£¸óºÐºñ ³ú
Çϼöü¼±Á¾ÇÑÀÚ¿¡¼­ Á¾¾çÀÇ ¿ÏÀüÇÑ Á¦°Å¸¦ ¸ñÇ¥·Î ¼ö¼úÀ» ½ÃÇàÇÏ¿´°í, ÀÌ¿¡ µû¸¥ Ä¡·á°á°ú
¿Í ¼ö¼ú·Î Á¾¾çÀÇ ¿ÏÀüÁ¦°Å°¡ ºÒ°¡´ÉÇÏ¿´´ø ȯÀÚ¿¡¼­ÀÇ ¿øÀÎ ¹× º¸Á¸Àû Ä¡·á¸¦ ½ÃÇàÇÑ °á°ú
¸¦ ºÐ¼®ÇÏ¿© ¼ºÀåÈ£¸£¸óºÐºñ ³úÇϼöü ¼±Á¾È¯ÀÚÀÇ Ä¡·áÀü·«À» Á¦½ÃÇÏ°íÀÚÇÑ´Ù.
#ÃÊ·Ï#
The goals of the pituitary tumor are restoration of normal pituitary function and
relieving the mass effect on the adjacent normal brain structures. The main purpose of
this study is to analyze our surgical removal. The surgical results were reviewed in 36
patients treated between 1993 and 1997. The criteria of clinical remission are
postoperative basal GH less than 5ng/ml and suppression of GH less than 2ng/ml in
oral glucose tolerance test. As the results, 25 of 36 patients(69.4%) achieved surgical
remission. Eleven patients who could not achieve remission by surgery were treated
with medical treatment(octreotide, bromocriptine) and Gamama-knife surgery. In
conclusion, the tumor morphology and extensiveness of tumor removal were well
correlated with surgical outcome, and the aggressive resection of tumor seems to be
most important factor achieving remission in GH secretion pituitary adenomas.

Å°¿öµå

Growth hormone; Pituitary adenoma; Bromocriptine; Otreotide; Gamma-knife surgery.;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS